Zenas BioPharma shares were trading at $27.02 as of February 19, reflecting a trailing P/E of 1.93. Analysts project revenues climbing to $30 million in 2026 with commercialization of obexelimab, positioning the company to transition from pre-revenue stage to commercial market and potentially deliver high returns on execution.

Obexelimab targets IgG4-Related Disease, a market with no approved therapies, offering an at-home treatment that preserves B cells and reduces infection risk. Early 2026 trial results showed efficacy below “best-in-class” benchmarks, underscoring regulatory and commercial binary outcomes, while additional studies in Warm Autoimmune Hemolytic Anemia and Multiple Sclerosis expand its indication pipeline.

With approximately $270 million in cash at the start of 2026, Zenas BioPharma can fund operations through 2028 and pursue in-licensing to broaden its pipeline. Early commercialization will incur high marginal costs, but successful scale-up of obexelimab sales could create significant asymmetric upside relative to current valuation.

The stock’s 50% decline in January 2026 highlights sensitivity to trial data and market sentiment, posing talent retention and execution challenges. If regulatory filings and rollout proceed flawlessly, market capitalization could expand up to fivefold, driven by obexelimab’s potential as a global standard of care.